Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04280367
Other study ID # APHP191093
Secondary ID 2019-A02663-54
Status Completed
Phase
First received
Last updated
Start date January 28, 2020
Est. completion date May 29, 2020

Study information

Verified date August 2023
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of the study aims to study transition toward schizophrenia in patients with learning disorders, and to compare the risk between patients with specific learning disorders, and patients with complexed learning disorders (by two types: patients with other neuro-developmental disorders including executive function disorders, and patients with anxiety).


Description:

As secondary objectives, the study aims to: - argue the clinical predicted markers (neuropsychological) transition toward psychosis. - test the feasibility and the acceptability of a early diagnosis for a potential applicable guidance for different referent centers of learning in French territory. - have a better classification of patients with learning disorders in order to target a prospective primary prevention of risk of psychosis via the questionnaires (AQ of Baron-Cohen: Autism-spectrum quotient auto-questionnaire; Inventory of Beck Anxiety Inventory, auto-questionnaire for panic disorder and general anxiety; Liebowitz Social Anxiety Scale). - improve identification of the early signs and the early emerging psychological diseases intervention management (schizophrenia). - Psychic disability: prevent and reduce non-seeking care and accompaniment situations, and risk of rupture of care. - permitting better care of psychosocial rehabilitation with cognitive evaluation. This study will be conducted in Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP, in France.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 29, 2020
Est. primary completion date May 29, 2020
Accepts healthy volunteers No
Gender All
Age group 15 Years to 30 Years
Eligibility Inclusion Criteria: - Patients born between 1990 and 2005, have been cared by Dr Schlumberger in 2014 in the center of language and learning disorders at Raymond Poincaré hospital; - With severe learning disorders: deficiency in school work, need at least one medical appointment and long-term rehabilitation in the center of language and learning disorders at Raymond Poincaré hospital; - Affiliated to a social protection schema; - Written informed consent signed. Exclusion Criteria: - Absence of learning disorder; - Intellectual deficiency; - Epilepsia; - Patients who will performed follow-up at Chartres city; - Patients under guardianship or curatorship; - Foreign patients under AME schema, a medical help from the state in France.

Study Design


Intervention

Diagnostic Test:
Standardised semi-structured talk
Comprehensive assessment of at-risk mental states (CAARMS) will be used.
Autistic spectre disorder screening
Autism-spectrum quotient (AQ) auto-questionnaire will be used.
Anxiety measuring
An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.

Locations

Country Name City State
France Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré Garches

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Semi-structured interview Assessement with Comprehensive Assessment of At-Risk Mental States (CAARMS) during 6 to 90 minutes at the center of Raymond Poincaré hospital.
The unique collection during the interview, quotation of each patient will be given from the assessement.
There will be 4 groups by the results: CAARMS negative subjects, vulnerable subjects, attenuated psychosis subjects and subjects with brief and limited intermittent psychotic syndrome. The further statistic comparison will be done between the 3 last groups classified with results of CAARMS.
At baseline
Secondary Autistic screening Autism-spectrum quotient (AQ) auto-questionnaire will be used to evaluate difficulty in social interaction. At baseline
Secondary Anxiety measuring An inventory for measuring clinical anxiety: Beck Anxiety Inventory At baseline
Secondary Social interaction difficulty evaluation Liebowitz Social Anxiety Scale as questionnaire At baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A